Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

bNAb

- PMLiVE

Gilead’s Veklury WHO recommendation expanded for treatment of severe COVID-19

The antiviral showed a 17% lower relative risk of death or progression compared to standard of care

- PMLiVE

Gilead Sciences announce positive results for Trodelvy in breast cancer patients

HR+/HER2- breast cancer accounts for around 70% of all new cases, or nearly 400,000 diagnoses worldwide each year

- PMLiVE

NHS England launches hepatitis C screening scheme to reach 2030 elimination goal

The new scheme could help diagnose up to 80,000 people who do not know they have hepatitis C

- PMLiVE

Gilead Sciences set to acquire MiroBio in deal worth over $400m

The UK biotech is a spin-out of Oxford University and focuses on research into autoimmune diseases

- PMLiVE

Gilead announces positive Biktarvy data for HIV and hepatitis B

The results were presented at the 24th International AIDS Conference

- PMLiVE

GSK’s ViiV and Medicines Patent Pool agree deal for HIV prevention

The agreement aims to expand access to HIV prevention in the developing world

- PMLiVE

Gilead’s COVID-19 drug Veklury recommends for approval by CHMP

If approved by the EC, Veklury will become the only direct-acting antiviral with full marketing authorisation in the EU

- PMLiVE

Gilead invests $85m in Gilead Foundation towards health equity progress

The donation follows an endowment announced by the company in 2021 to recapitalise the Foundation

- PMLiVE

Gilead Sciences supports Kigali Declaration for neglected tropical diseases

1.7 billion people around the world are affected by tropical diseases, which are prevalent in tropical areas and mostly affect impoverished communities

Roche Basel Switzerland

Roche collaborates with Global Fund to strengthen critical diagnostics infrastructure

The partnership is focused on helping patients with HIV and TB in low- and middle-income countries

- PMLiVE

Gilead signs $300m deal with Dragonfly to advance immunotherapies

The partnership will make use of Dragonfly’s oncology and inflammatory disease research capabilities

- PMLiVE

BMS Foundation announces Robert A Winn Diversity in Clinical Trials Award Program

The $100m initiative was started in 2020 to increase diversity in clinical trials

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links